CD274 and neoplasm: Most importantly, herein, using a cohort of 189 tumors from 10 tumor types (where PD-L1 IHC by TPS, CPS, or IC was ordered clinically), IRS status outperformed PD-L1 IHC, or combined PD-L1 IHC and TMB status, for predicting anti-PD-(L)1 rwPFS.